Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | GNRHR | P30968 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449059 | 1.00 | KDM4E (0.53) | KDM4EPKMIDO1TDO2CYP2C9 | |
| SCHEMBL22533699 | 0.81 | CYP2C9 (0.58) | KDM4EPKMCYP2C9ACKR3NAMPT | |
| SCHEMBL4592664 | 0.80 | ACKR3 (0.56) | KDM4EPKMIDO1TDO2CYP2C9 | |
| SCHEMBL3447823 | 0.80 | ACKR3 (0.56) | KDM4EPKMIDO1TDO2CYP2C9 | |
| SCHEMBL3447821 | 0.80 | ACKR3 (0.56) | KDM4EPKMIDO1TDO2CYP2C9 | |
| SCHEMBL3447174 | 0.79 | CYP2C9 (0.55) | KDM4EPKMCYP2C9NAMPTMEN1 | |
| SCHEMBL3449048 | 0.79 | CYP2C9 (0.53) | KDM4EPKMIDO1TDO2CYP2C9 | |
| SCHEMBL3449051 | 0.79 | CYP2C9 (0.53) | KDM4EPKMIDO1TDO2CYP2C9 | |
| SCHEMBL3447178 | 0.79 | CYP2C9 (0.55) | KDM4EPKMCYP2C9NAMPTMEN1 | |
| SCHEMBL14731327 | 0.79 | KDM4E (0.69) | KDM4EPKMIDO1TDO2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | KDM4E 2242/4885PKM 1858/4885IDO1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.